NCT00762632View on ClinicalTrials.gov

Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

June 30, 2012

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

NILOTINIB

400 mg Nilotinib bid (total daily dose 800 mg) should be continued 25 weeks

DRUG

EVEROLIMUS

Everolimus at 2,5 mg/day should be continued 25 weeks.

Trial Locations (1)

81675

Medical faculty of the Technical University Munich, Munich

All Listed Sponsors
lead

Technical University of Munich

OTHER

NCT00762632 - Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter